Bausch Health stock gained 1.22 percent on October 2, 2026

Published on 10/04/2026 at 19:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch Health stock closed at USD 5.80 on October 2, 2026, after a 1.22 percent gain. Q2 revenue rose 13 percent to USD 2.852 billion.

BHC, CA0717341071, Illustration mit AI erstellt.

Bausch Health stock (ISIN CA0717341071) closed at USD 5.80 on the NYSE on October 2, 2026, gaining 1.22 percent from the prior close and placing the company at a market capitalization of USD 2.2 billion. The move followed a second quarter in which revenue and adjusted earnings both advanced, while management raised its full-year outlook.

Revenue growth sets the pace

For the second quarter of 2026, Bausch Health reported revenue of USD 2.852 billion, up 13 percent year over year, according to Yahoo Finance. Adjusted earnings per diluted share increased 40 percent to USD 1.26, giving investors a more favorable operating comparison than the statutory diluted EPS of USD 0.68 reported for Q2 2026.

The company also reported adjusted EBITDA of USD 1.075 billion, a 28 percent year-over-year increase, and adjusted cash flow from operations of USD 637 million, up 44 percent. The combination matters because cash generation gives Bausch Health room to fund product expansion while it continues to manage a complex specialty-pharmaceutical portfolio.

Guidance moves higher

At the half-year mark, management raised its full-year guidance for Bausch Health excluding Bausch + Lomb. The new revenue range is USD 5.350 billion-5.500 billion, the adjusted EBITDA range is USD 3.025 billion-3.100 billion, and adjusted cash flow from operations is guided to USD 1.400 billion-1.475 billion, according to the company's investor-relations materials at Bausch Health. The midpoint of the revenue range implies 5 percent year-over-year growth, while the EBITDA midpoint implies 10 percent growth.

The latest commercial expansion adds a second angle to that guidance. On September 8, 2026, Bausch Health and YUN announced an extension of their probiotic skincare partnership into Mexico and five additional markets across Europe and Central Asia, as reported by Bausch Health. The company said the rollout builds on a 2025 launch in Poland and includes acne and eczema products.

Analysts see higher value

Analyst opinion remains divided despite the stronger operating figures. MarketBeat reported on September 18, 2026, that seven rating firms gave Bausch Health a Reduce consensus, with one Sell rating and six Hold ratings. The average 12-month price target was USD 8.00.

A separate October 2, 2026 report from MarketBeat said Zacks Research raised its Q3 2028 EPS forecast to USD 0.82 from USD 0.81 and maintained a Strong Buy rating. The contrast between a cautious broader consensus and selective bullish research leaves execution against the new guidance as the central test for the stock.

Stock closes near yearly midpoint

Bausch Health stock closed at USD 5.80 on October 2, 2026, with a session range of USD 5.61-5.87. Its 52-week range was USD 4.33-8.00, putting the close USD 2.20 below the yearly high and USD 1.47 above the low.